Radio Isotope Therapy of America   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Houston TX United States (2004)

Organization Overview

First Clinical Trial
2005
NCT00442533
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Ebrahim Delpassand | Ebrahim S. Delpassand

Active Ingredients

Drugs in Phase 3 Trials (1)

in111-octreoscan (1 trial)

Drugs in Phase 2 Trials (3)

Ga 68 PSMA-11 (Illuccix) (1 trial)

gallium-68-dotatate (netspot) (1 trial)

lutetium dotatate lu-177 (Lutathera) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Neuroendocrine (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4